<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fluorescein and benoxinate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fluorescein and benoxinate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fluorescein and benoxinate: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="134987" href="/d/html/134987.html" rel="external">see "Fluorescein and benoxinate: Pediatric drug information"</a> and <a class="drug drug_patient" data-topicid="135127" href="/d/html/135127.html" rel="external">see "Fluorescein and benoxinate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F5095228"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Altafluor Benox;</li>
<li>Altafluor [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F55361457"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Fluress [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F5095232"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anesthetic, Topical;</li>
<li>
                        Diagnostic Agent;</li>
<li>
                        Ophthalmic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F5095251"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7058a621-1a7d-4501-b189-f8cbe1e81566">Ophthalmic procedures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Ophthalmic procedures:</b>
<b>Ophthalmic:</b> Instill 1 or 2 drops in the eye as needed.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991294"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988612"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F55753866"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F51310101"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="134987" href="/d/html/134987.html" rel="external">see "Fluorescein and benoxinate: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7058a621-1a7d-4501-b189-f8cbe1e81566">Ophthalmic procedures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ophthalmic procedures: </b>Infants, Children, and Adolescents: Ophthalmic: Instill 1 or 2 drops into each eye as needed before procedure.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51344124"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51344125"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F5095241"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Blurred vision, burning sensation of eyes, eye irritation, ocular hyperemia, punctate keratitis, stinging of eyes</p></div>
<div class="block coi drugH1Div" id="F5095237"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to fluorescein, benoxinate, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F5095238"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For topical ophthalmic use only. To avoid contamination, do not touch dropper tip to eyelids or other surfaces. The anesthetized eye should be protected from irritation, foreign bodies, and rubbing to prevent inadvertent damage.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prolonged use: Prolonged use or abuse may lead to corneal epithelial toxicity, manifesting as epithelial defects, which may progress to permanent corneal damage and vision loss.</p></div>
<div class="block foc drugH1Div" id="F5095254"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Altafluor: Fluorescein sodium 0.25% and benoxinate hydrochloride 0.4% (5 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Altafluor Benox: Fluorescein sodium 0.25% and benoxinate hydrochloride 0.4% (5 mL) [contains chlorobutanol (chlorobutol)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Fluorescein sodium 0.25% and benoxinate hydrochloride 0.4% (5 mL); Fluorescein sodium 0.3% and benoxinate hydrochloride 0.4% (5 mL)</p></div>
<div class="block geq drugH1Div" id="F5095230"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16324142"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Fluorescein-Benoxinate Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25-0.4% (per mL): $1.57</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F55361458"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fluress: Fluorescein sodium 0.25% and benoxinate hydrochloride 0.4% ([DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Fluorescein sodium 0.25% and benoxinate hydrochloride 0.4% ([DSC])</p></div>
<div class="block adm drugH1Div" id="F5095252"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Ophthalmic:</b> For topical ophthalmic use only; avoid touching tip of dropper to eye, fingers, or other surfaces. Avoid touching eye for ~20 minutes after instillation; protect eye from irritation, chemicals, foreign bodies, and rubbing to prevent inadvertent damage.</p></div>
<div class="block admp drugH1Div" id="F52614252"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Ophthalmic: For topical ophthalmic use only; avoid touching tip of dropper to eye, fingers, or other surfaces. Avoid touching eye for ~20 minutes after instillation; anesthetic effects decrease sensitivity and may increase risk of injury; protect eye from irritation, chemicals, foreign bodies, and rubbing to prevent inadvertent damage.</p></div>
<div class="block use drugH1Div" id="F5095233"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Ophthalmic procedures: </b>For use in ophthalmic procedures when a topical disclosing agent is needed along with an anesthetic.</p></div>
<div class="block cyt drugH1Div" id="F46769543"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F46769540"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May enhance the therapeutic effect of Benoxinate. Specifically, the effects of benoxinate may be prolonged.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine: Local Anesthetics may enhance the adverse/toxic effect of BUPivacaine.  Management: Avoid using any additional local anesthetics within 96 hours after insertion of the bupivacaine implant (Xaracoll) or bupivacaine and meloxicam periarticular solution (Zynrelef) or within 168 hours after subacromial infiltration (Posimir brand).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine (Liposomal): Local Anesthetics may enhance the adverse/toxic effect of BUPivacaine (Liposomal).  Management: Liposomal bupivacaine should not be administered with local anesthetics, but may be administered 20 minutes or more after lidocaine. Avoid all local anesthetics within 96 hours after administration of liposomal bupivacaine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Local Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept.  Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.  This interaction does not appear to apply to other uses of these agents in combination.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F5095235"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. Refer to Fluorescein monograph.</p></div>
<div class="block brc drugH1Div" id="F5095236"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Refer to Fluorescein monograph.</p></div>
<div class="block pha drugH1Div" id="F5095247"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Fluorescein is a diagnostic dye; benoxinate is a rapid acting anesthetic with short duration.</p></div>
<div class="block phk drugH1Div" id="F51310095"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: 5 to 45 seconds</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: ~20 minutes (single administration); effect may be prolonged by subsequent administration (10 to 20 minutes after last administration)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F49626930"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Flurekain | Thilorbin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Fluress</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Combiflure</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Thilorbin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Thilorbin</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Oxybuprokain-fluorescein sad</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Oftan flurekain</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Oftan flurekain</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Flurekain</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Combiflure</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Oftan flurekain</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Combiflure</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Fluress</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Thilorbin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Altafluor benox | Fluorescein sodium and benoxinate hcl | Fluorescein sodium and benoxinate hydrochloride | Flurate | Fluress | Flurox</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Fluotest multidose</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Fluress | Optax</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Altafluor Benox (fluorescein sodium and benoxinate hydrochloride ophthalmic solution) [prescribing information]. Aquebogue, NY: Altaire Pharmaceuticals, Inc; December 2017.</div>
</li>
<li>
<div class="reference">
                  Fluorescein sodium and benoxinate hydrochloride [prescribing information]. Bridgewater, NJ: Bausch Health US LLC; March 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 8913 Version 115.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
